carlyle is a global investment firm with $325 billion of assets under management. our purpose is to invest wisely and create value on behalf of our investors, portfolio companies and the communities in which we live and invest. founded in 1987 in washington, dc, carlyle has grown into one of the world’s largest and most successful global investment firms, with nearly 1,850 people operating in 26 offices across five continents.
Company profile
Ticker
CG, CGABL
Exchange
Website
CEO
William E. Conway, Jr.
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Carlyle Group L.P.
SEC CIK
Corporate docs
Subsidiaries
Abingworth Bioventures 8 GP LP • Abingworth Bioventures GP Limited • Abingworth Bioventures V GP limited • Abingworth CCD GP Limited • Abingworth Clinical Co-Development Fund 2 GP LP • Abingworth German Designated LP Corp. • Abingworth Management Inc • Abingworth Second Partner Limited • ACP 2021 Agg. GP, LLC • ACP 2022 Agg. GP, LLC ...
IRS number
452832612
SEC advisor number
801-52462
FINRA CRD number
111128
AUM ?
$143.79 bn
(as of 29 Mar 20)
Accounts
561
(as of 29 Mar 20)
Employees
864
(286 investment advisory or research)
Address
Carlyle Group Inc
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVENUE, N.W.
WASHINGTON
DC 20004
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVENUE, N.W.
WASHINGTON
DC 20004
Phone
202 729 5626
CG stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
Carlyle Reports Second Quarter 2023 Financial Results
2 Aug 23
8-K
Carlyle Names John Redett as Chief Financial Officer and Head of Corporate Strategy
20 Jun 23
S-8
Registration of securities for employees
16 Jun 23
8-K
Departure of Directors or Certain Officers
1 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Carlyle Reports First Quarter 2023 Financial Results
3 May 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
8-K
Carlyle Appoints Sharda Cherwoo as an Independent Director
26 Apr 23
Transcripts
CG
Earnings call transcript
2023 Q2
2 Aug 23
CG
Earnings call transcript
2023 Q1
4 May 23
CG
Earnings call transcript
2022 Q4
7 Feb 23
CG
Earnings call transcript
2022 Q3
8 Nov 22
CG
Earnings call transcript
2022 Q2
28 Jul 22
CG
Earnings call transcript
2022 Q1
28 Apr 22
CG
Earnings call transcript
2021 Q4
3 Feb 22
CG
Earnings call transcript
2021 Q3
28 Oct 21
CG
Earnings call transcript
2021 Q2
29 Jul 21
CG
Earnings call transcript
2021 Q1
30 Apr 21
Latest ownership filings
4
SOLENO THERAPEUTICS INC
2 Oct 23
3
John C. Redett
2 Oct 23
4
CommScope Holding Company, Inc.
2 Oct 23
SC 13G
Complete Solaria, Inc.
22 Sep 23
SC 13D/A
Carlyle Credit Income Fund
14 Sep 23
4
Carlyle Credit Income Fund
14 Sep 23
4
Carlyle Credit Income Fund
30 Aug 23
SC 13D/A
Carlyle Credit Income Fund
30 Aug 23
4
HARVEY M SCHWARTZ
25 Aug 23
SC 13D/A
eFFECTOR Therapeutics, Inc.
18 Aug 23
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 875.70 mm | 875.70 mm | 875.70 mm | 875.70 mm | 875.70 mm | 875.70 mm |
| Cash burn (monthly) | 50.40 mm | 36.18 mm | 23.33 mm | (no burn) | 245.50 mm | 55.82 mm |
| Cash used (since last report) | 157.17 mm | 112.81 mm | 72.77 mm | n/a | 765.60 mm | 174.07 mm |
| Cash remaining | 718.53 mm | 762.89 mm | 802.93 mm | n/a | 110.10 mm | 701.63 mm |
| Runway (months of cash) | 14.3 | 21.1 | 34.4 | n/a | 0.4 | 12.6 |
Institutional ownership, Q2 2023
| 13F holders | Current |
|---|---|
| Total holders | 387 |
| Opened positions | 35 |
| Closed positions | 72 |
| Increased positions | 143 |
| Reduced positions | 134 |
| 13F shares | Current |
|---|---|
| Total value | 6.30 tn |
| Total shares | 366.57 mm |
| Total puts | 941.20 k |
| Total calls | 1.82 mm |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Carlyle Group Management L.L.C. | 152.13 mm | $5.75 bn |
| Vanguard | 24.53 mm | $783.79 bn |
| BLK Blackrock | 21.91 mm | $700.15 bn |
| MS Morgan Stanley | 19.56 mm | $624.96 bn |
| Capital World Investors | 18.65 mm | $596.01 bn |
| Mubadala Investment Co PJSC | 16.89 mm | $795.65 mm |
| Alkeon Capital Management | 12.13 mm | $387.40 bn |
| Vulcan Value Partners | 11.24 mm | $359.73 bn |
| Ariel Investments | 5.45 mm | $174.01 bn |
| William Blair Investment Management | 5.35 mm | $171.02 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Sep 23 | Carlyle Group Inc | Series A Convertible Preferred Stock Common Stock | Other | Acquire J | Yes | No | 0 | 15,548 | 0.00 | 1,146,324 |
| 28 Sep 23 | Carlyle Group Inc | Common Stock | Conversion | Acquire C | Yes | No | 1.75 | 329,930 | 577.38 k | 1,531,436 |
| 28 Sep 23 | Carlyle Group Inc | Prefunded Warrants Common Stock | Conversion | Acquire C | Yes | No | 1.75 | 762,126 | 1.33 mm | 762,126 |
| 28 Sep 23 | Carlyle Group Inc | Tranche A Warrants Common Stock | Conversion | Dispose C | Yes | No | 1.75 | 1,092,056 | 1.91 mm | 0 |
| 12 Sep 23 | Subsidiary Holdings L.L.C. CG | Shares of Beneficial Interest | Buy | Acquire P | No | No | 8.52 | 1,269,537 | 10.82 mm | 4,785,628 |
| 28 Aug 23 | Subsidiary Holdings L.L.C. CG | Shares of Beneficial Interest | Buy | Acquire P | Yes | No | 8.3 | 504,042 | 4.18 mm | 504,042 |
| 28 Aug 23 | Subsidiary Holdings L.L.C. CG | Shares of Beneficial Interest | Buy | Acquire P | No | No | 8.3 | 3,012,049 | 25.00 mm | 3,012,049 |
| 28 Aug 23 | Subsidiary Holdings L.L.C. CG | Contract to Purchase Shares of Beneficial Interest | Buy | Acquire P | Yes | No | 8.3 | 1,303,187 | 10.82 mm | 1,303,187 |
News
U.S. Department Of Veterans Affairs Awards Acentra Health, Backed By Carlyle, $52.3M Financial Services Center Contract For Claims Adjudication, Provider Access, Data Analytics And Visualization
3 Oct 23
'Carlyle Is Dismantling U.S. Consumer Investing Team In Buyout Shift; Four Dealmakers Who Made Consumer Bets Were Asked To Leave; Shift In Focus Will Affect About A Dozen Carlyle Employees' - Bloomberg News
2 Oct 23
SEC Collects Thousands Of Messages In Wall Street Messaging App Investigation
26 Sep 23
10 Financials Stocks With Whale Alerts In Today's Session
12 Sep 23
What's Going On With BlackBerry Stock Monday?
11 Sep 23
Press releases
U.S. Department of Veterans Affairs Awards Acentra Health $52.3M Financial Services Center Contract for Claims Adjudication, Provider Access, Data Analytics and Visualization
3 Oct 23
CARLYLE JOINS GTCR AS STRATEGIC INVESTOR IN CAPTRUST
19 Sep 23
Carlyle Credit Income Fund (CCIF) Completes Initial Transition Plan, Declares Monthly Dividends and Announces August 31, 2023 Net Asset Value
12 Sep 23
Acentra Health Awarded Contract Extension Overseeing Utilization Management Services for Florida Medicaid
7 Sep 23
Acentra Health CEO Todd Stottlemyer Named by Virginia Business to 2023 Power List
5 Sep 23